Abbildung 8: KHK - Sekundärprävention
So, ACEIs, by both decreasing A II and increasing bradykinin levels offer possible anti ischemic effects, which could lead to secondary prevention of cardiovascular events in the treatment of coronary artery disease patients. inhibition in secondary prevention, comes directly from the following properties of perindopril, as demonstrated in human or experimental models: anti-atherosclerotic action, action on plaque rupture reduction, improvement of vascular endothelium, enhanced fibrinolysis, modulation of the neurohormonoally-induced arterial vasoconstriction, blood pressure lowering action in reducing left ventricular hypertrophy.